Chad Robins Sells 321,324 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 321,324 shares of Adaptive Biotechnologies stock in a transaction on Monday, August 17th. The stock was sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the completion of the transaction, the chief executive officer owned 2,180,518 shares in the company, valued at approximately $54,687,391.44. The trade was a 12.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Adaptive Biotechnologies Trading Down 0.2%

Shares of ADPT stock opened at $25.44 on Friday. The business has a 50-day moving average of $21.89 and a 200 day moving average of $17.28. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. Adaptive Biotechnologies Corporation has a 1-year low of $12.00 and a 1-year high of $26.16. The stock has a market capitalization of $4.06 billion, a PE ratio of -62.05 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same period last year, the business earned ($0.17) EPS. Adaptive Biotechnologies’s revenue was up 21.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ADPT shares. JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Guggenheim upped their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Piper Sandler boosted their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus price target of $24.42.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Analysts maintain a broadly constructive view, with five Buy ratings, one Hold and one Sell. BTIG Research and TD Cowen recently raised their price targets to $25 and $28, respectively, while the consensus rating remains “Moderate Buy.” Analyst and stock information
• Positive Sentiment: Institutional ownership remains high at 99.17%, and several hedge funds increased their positions, including Jennison Associates, which more than doubled its stake. Institutional ownership information
• Positive Sentiment: The company’s latest quarterly revenue reached $71.55 million, exceeding estimates of $65.44 million and increasing 21.5% year over year, supporting the growth case for its immune-receptor sequencing business. Quarterly results
• Neutral Sentiment: ADPT has rallied substantially, trading near its 52-week high and above both its 50-day and 200-day moving averages. However, the consensus price target of $24.42 is below recently reported trading levels, suggesting limited near-term upside based on current estimates.
• Negative Sentiment: Multiple insiders sold substantial positions: CEO Chad Robins sold approximately 600,000 shares for nearly $14.9 million across August 17–18, while Director Peter Neupert sold 124,690 shares for $3.14 million and Director Robert Hershberg sold 30,664 shares for $748,000. The transactions reduced the directors’ holdings by roughly 40%–49% and the CEO’s ownership by about 11%–13%, potentially weighing on investor confidence. Insider selling report
• Negative Sentiment: Adaptive Biotechnologies missed quarterly EPS expectations, reporting a loss of $0.25 per share versus the anticipated loss of $0.13. The company remains unprofitable, with analysts expecting a full-year loss of approximately $0.40 per share.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at $28,000. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies in the second quarter worth $35,000. EverSource Wealth Advisors LLC increased its position in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the last quarter. KBC Group NV bought a new position in Adaptive Biotechnologies in the first quarter valued at about $45,000. Finally, Assetmark Inc. lifted its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.